There are many new H-1-receptor antagonists. Their clinical pharmacology, a
s objectively measured in pharmacokinetic and pharmacodynamic studies, diff
ers considerably The importance of understanding these differences should n
ot be underestimated, as they directly influence H-1-antagonist dose and do
se interval, and they facilitate H-1-antagonist use in special populations,
for example, the elderly. Without a doubt, pharmacokinetic and pharmacodyn
amic studies of H-1-antagonists provide a scientific foundation for using t
hese medications with optimal effectiveness and safety.